Compassionate Treatment of Brainstem Tumors with Boron Neutron Capture Therapy: A Case Series

Brainstem tumors are heterogenous and cancerous glioma tumors arising from the midbrain, pons, and the medulla that are relatively common in children, accounting for 10% to 20% of all pediatric brain tumors. However, the prognosis of aggressive brainstem gliomas remains extremely poor despite aggres...

Full description

Bibliographic Details
Main Authors: Yi-Wei Chen, Yi-Yen Lee, Chun-Fu Lin, Ting-Yu Huang, Shih-Hung Ke, Pei-Fan Mu, Po-Shen Pan, Jen-Kun Chen, Tien-Li Lan, Ping-Chuan Hsu, Muh-Lii Liang, Hsin-Hung Chen, Feng-Chi Chang, Chih-Chun Wu, Shih-Chieh Lin, Jia-Cheng Lee, Shih-Kuan Chen, Hong-Ming Liu, Jinn-Jer Peir, Hui-Yu Tsai, Ko-Han Lin, Nan-Jing Peng, Kuan-Hsuan Chen, Yuan-Hung Wu, Yu-Mei Kang, Wan-Chin Yang, Shueh-Chun Liou, Wei-Hsuan Huang, Hiroki Tanaka, Tai-Tong Wong, Yee Chao, Fong-In Chou
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Life
Subjects:
Online Access:https://www.mdpi.com/2075-1729/12/4/566
Description
Summary:Brainstem tumors are heterogenous and cancerous glioma tumors arising from the midbrain, pons, and the medulla that are relatively common in children, accounting for 10% to 20% of all pediatric brain tumors. However, the prognosis of aggressive brainstem gliomas remains extremely poor despite aggressive treatment with chemotherapy and radiotherapy. That means there are many life-threatening patients who have exhausted all available treatment options and are beginning to face end-of-life stage. Therefore, the unique properties of highly selective heavy particle irradiation with boron neutron capture therapy (BNCT) may be well suited to prolong the lives of patients with end-stage brainstem gliomas. Herein, we report a case series of life-threatening patients with end-stage brainstem glioma who eligible for Emergency and Compassionate Use, in whom we performed a scheduled two fractions of salvage BNCT strategy with low treatment dosage each time. No patients experienced acute or late adverse events related to BNCT. There were 3 patients who relapsed after two fractionated BNCT treatment, characterized by younger age, lower T/N ratio, and receiving lower treatment dose. Therefore, two fractionated low-dose BNCT may be a promising treatment for end-stage brainstem tumors. For younger patients with low T/N ratios, more fractionated low-dose BNCT should be considered.
ISSN:2075-1729